CDC7 kinase inhibitors and uses thereof

Patent metadata

Field	Value
Publication number	US-12109189-B2
Application number	US-202318138351-A
Country	US
Kind code	B2
Filing date	Apr 24, 2023
Priority date	Mar 8, 2010
Publication date	Oct 8, 2024
Grant date	Oct 8, 2024

Abstract

The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B):

or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

First claim

What is claimed is:

1. A method for treating a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the Formula (A-2):

or a pharmaceutically acceptable salt thereof,
wherein:
each instance of R 1 and R 4 is independently selected from the group consisting of hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl;
each instance of R 2 and R 3 is independently selected from the group consisting of hydrogen, halogen, —OH, substituted hydroxyl, —SH, substituted thiol, —NH 2 , substituted amino, —CN, —NO 2 , carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 2 and R 3 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group;
R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl,
with the proviso that the compound cannot be:

2. The method of claim 1 , wherein the compound is of the Formula (A-3) or (A-4):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is of the Formula (A-5) or (A-6):

or a pharmaceutically acceptable salt thereof.

4. The method according to claim 1 , wherein the compound is an inhibitor of a protein kinase.

5. The method according to claim 4 , wherein the protein kinase is Cdc7 kinase or the Dbf4 regulatory subunit of Cdc7 kinase.

6. The method according claim 1 , wherein the cancer is selected from the group consisting of bone, brain, connective tissue, endocrine glands, adrenal cortex, endometrium, germ cells, head and neck, larynx and hypopharynx, mesothelioma, muscle, rectum, renal, small intestine, soft tissue, testis, ureter, vagina, and vulva; bladder cancer; breast cancer; colon cancer; kidney cancer; liver cancer; lung cancer; esophagus cancer; gallbladder cancer; ovarian cancer; pancreatic cancer; stomach cancer; cervical cancer; thyroid cancer; prostate cancer; papillary thyroid carcinoma; genitourinary malignancies; retinoblastoma; Wilms tumor; myelodysplastic syndrome; plasma cell neoplasia; paraneoplastic syndromes; renal cell carcinoma; Ewing's sarcoma; desmoplastic small round cell tumors; mesothelioma; skin cancer; hematologic cancers; fibrosarcoma; rhabdomyosarcoma; astrocytoma, neuroblastoma, glioblastoma, schwannomas; seminoma, teratocarcinoma, osteosarcoma, xeroderma pegmentosum, keratoxanthoma, thyroid follicular cancer, and Kaposi's sarcoma.

7. The method according to claim 6 , wherein the cancer is a hematologic cancer, ovarian cancer, lung cancer, prostate cancer, renal cell carcinoma, cervical cancer, glioblastoma, retinoblastoma, rhabdomyosarcoma, desmoplastic small round cell tumor, breast cancer, mesothelioma, melanoma, thyroid carcinoma, or Ewing's sarcoma.

8. The method accordingly to claim 1 , wherein the cancer comprises a genetic mutation selected from the group consisting of a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ALB kinase mutation, or combinations thereof.

9. The method according to claim 1 , wherein the cancer is a multi-drug resistant (MDR) cancer.

10. The method according to claim 1 , wherein the cancer is relapsed and/or refractory cancer.

11. The method according to claim 1 further comprising administering at least one other therapy or therapeutic agent.

12. The method according to claim 11 further comprising administering radiation.

13. The method of claim 6 , wherein the skin cancer is squamous cell carcinoma.

14. The method of claim 6 , wherein the hematologic cancers are hematopoietic cancers of lymphoid lineage selected from the group consisting of leukemia, acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

15. The method of claim 14 , wherein the non-Hodgkin's lymphoma is selected from the group consisting of mantle cell lymphoma (MCL), hairy cell lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia (CLL).

16. The method of claim 6 , wherein the hematologic cancers are hematopoietic cancers of myeloid lineage selected from the group consisting of multiple myeloma, chronic myeloid leukemia (CML), and acute myeloid leukemia (AML).

17. The method of claim 16 , wherein the acute myeloid leukemia (AML) is selected from the group consisting of acute megakaryoblastic leukemia (AMKL), myelodysplastic syndrome, and promyelocytic leukemia.

18. The method according to claim 6 , wherein the skin cancer is melanoma or cutaneous melanoma.

Assignees

• Sloan Kettering Inst Cancer Res

Inventors

• Frattini Mark G
• Djaballah Hakim
• Kelly Thomas J

Classifications

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• C07D493/18

  Bridged systems · CPC title

• C07D493/08

  Bridged systems · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title